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As a continuation of our research and with the aim of obtaining new 
antituberculosis agents which can improve the current chemotherapeutic 
antituberculosis treatments, forty-three new quinoxaline-2-carboxamide 1,4-di-N-oxide 
derivatives were synthesized and evaluated for in vitro antituberculosis activity against 
Mycobacterium tuberculosis strain H37Rv. Active compounds were also screened to 
assess toxicity to a VERO cell line. Results indicate that compounds with a methyl 
moiety substituted in position 3 and un-substituted benzyl substituted on the 
carboxamide group provide an efficient approach for further development of anti-
tuberculosis agents. 
 
Keywords: quinoxaline, N-oxides, anti-tuberculosis agents, Mycobacterium 
tuberculosis. 
 1. Introduction 
Tuberculosis (TB) is an infectious bacterial disease caused by Mycobacterium 
Tuberculosis (M.Tbc). The report published by WHO in 2009 established that there 
were an estimated 9.27 million incident cases of TB in 2007. This means an increase 
from the 9.24 million cases in 2006, the 8.3 million cases in 2000 and the 6.6 million 
cases in 1990. Although the total number of incident cases of TB is increasing, it must 
be said that the number of cases per capita is slowly decreasing.[1] Nevertheless, the 
continuing emergence of multidrug-resistant strains of M. tuberculosis (MDR-TB) will 
inevitably make it more difficult in the future to control TB. 
The global epidemiology of drug-resistant TB, particularly extremely drug-
resistant TB (XDR-TB), is unknown and the true magnitude of the problem is probably 
quite underestimated. MDR-TB, which is defined as TB caused by organisms that are 
resistant to isoniazid and rifampicin, continues to threaten the progress being made in 
controlling the disease. The emergence of XDR-TB, defined as a less common form of 
MDR-TB that is resistant not only to isoniazid and rifampicin but also to any one of the 
fluoroquinolones and to at least one of the second-line drugs (amikacin, capreomycin or 
kanamycin), has heightened this threat.[2] The recent influx of immigrants from 
countries endemic for disease and co-infection with human immunodeficiency virus 
(HIV) turns TB into a serious problem in developed countries.[3,4] The development of 
HIV co-infection with MDR-TB and XDR-TB highlights the urgent need for new drugs 
to extend the range of effective TB treatment options. 
Quinoxaline derivatives are a class of compounds that show very interesting 
biological properties and the interest in these compounds is growing within the field of 
medicinal chemistry. Quinoxaline 1,4-di-N-oxide derivatives even improve the 
biological results shown by their reduced analogues and are endowed with antiviral, 
anticancer, antibacterial and antiprotozoal activities.[5-9] There are many publications 
regarding 1,4-di-N-oxide derivatives, and more specifically alkyl and arylcarboxamide 
derivatives, in which their antibacterial and antimicrobial activities [10-14] have been 
reported or their capability to act as antitumoral agents [15, 16] has been clearly 
demonstrated, thereby reflecting the growing interest in these structures over the past 
forty years.  
 As a result of the anti-tuberculosis research project, our group has published 
several papers reporting a wide range of quinoxaline-1,4-di-N-oxide derivatives (Figure 
1) including a great variety of substituents in positions 2, 3, 6 and 7. With regard to 
position 2, carbonitrile derivatives appeared to be quite toxic [17-21]. Moreover, ketone, 
 carboxylate and carboxamide quinoxaline-1,4-dioxydes derivatives were actually 
patented in the 70's for their antibacterial activity.[12-15] 
 These studies have facilitated a wide structure-activity relationship (SAR) 
analysis which lead us to design a group of thirty-six 3-methylquinoxaline-2-
carboxamide 1,4-di-N-oxide derivatives that were prepared and tested against M.Tbc 
and to justify the design of the compounds presented in this paper.[22] 
Continuing with the antituberculosis project and in an attempt to establish the 
structural requirements necessary for the development of anti-tuberculosis drugs, nine 
series of quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives were proposed (Figure 
2). Several structural modifications were designed and can be summarized as follows: a) 
variation in the length of the aliphatic linker between the carboxamide group and the 
aromatic ring; b) modification of the substituent in position 3 by a phenyl (Series 1-3) 
and a methyl moiety (Series 4-9); c) substitution of a variety of aromatic rings (Series 4-
9). 
2. Chemistry 
Forty-three new 1,4-di-N-oxide-quinoxaline-2-carboxylic acid aryl amide 
derivatives were prepared according to the synthetic process illustrated in Scheme 1: 
Scheme 1. 
The synthesis of the new 1,4-di-N-oxide-quinoxaline derivatives (Series 1-9) 
was carried out by a variation of the Beirut reaction [23], where the appropriate 
benzofuroxanes (BFX) react with the corresponding β-ketoamide in the presence of 
calcium chloride and ethanolamine as catalysts.[22,24] 
The starting compounds, BFX, were obtained by previously described 
methods.[18,25] Compound 1 was commercially available whereas the rest of the β-
ketoamides were synthesized as follows: compound 2 was synthesized by Passerini 
reaction between the appropriate glyoxal and isocyanide [26]; compound 3 was 
synthesized by condensation of the corresponding ester and the appropriate aryl 
amine.[27] Compounds 4-9 were obtained through the acetoacetylation of 
corresponding aryl amines by diketene.[22,28] 
Quinoxaline derivatives were unsubstituted or substituted in positions 6 and 7 by 
chloro, fluoro or trifluoromethyl moiety as electron-withdrawing groups and by methyl 
or methoxy moiety as electron-releasing groups. When quinoxalines were prepared 
from monosubstituted-BFX, the formation of isomeric quinoxalines 1,4-di-N-oxide was 
observed. In most cases, the 7-substituted isomer prevailed over 6-substituted isomer, 
and when the methoxy substituted quinoxalines were prepared, only the 7-isomer was 
obtained, as previously described.[29,30] 
 3. Pharmacology 
In vitro evaluation of the antituberculosis activity was carried out within the 
Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF) screening 
program for the discovery of novel drugs for the treatment of tuberculosis.[31] The 
Southern Research Institute coordinates the overall program under the direction of the 
U.S. National Institute of Allergy and Infectious Disease (NIAID). 
The purpose of the screening program is to provide a resource whereby new 
experimental compounds can be tested for their ability to inhibit the growth of virulent 
Mycobacterium tuberculosis (M.Tbc.). Biological tests have been performed according 
to previously described methods.[32] 
4. Results and discussion 
Structure and biological values of new synthesized quinoxaline 1,4-di-N-oxide 
derivatives are reported in Table 1. Compounds are assayed against M.Tbc. H37Rv in 
order to determine the IC90. Compounds showing values of ≤10µg/mL are considered as 
active and move on to the secondary screening. Cytotoxicity is assayed in VERO cells 
and the CC50 is determined from the dose-response curve. Next, the IC90 and CC50 
values are formed into a ratio termed Selectivity Index (SI). Compounds showing a 
SI≥10 are considered active for antitubercular activity. 
Table 1. 
As can be observed in Table 1, thirteen of the forty-three evaluated compounds 
passed the cut off established by the TAACF at the primary screening level and moved 
on to the secondary screening level. Compounds 2b and 4d were identified as the most 
interesting with a SI higher than 10. 
Some structure-activity relationships were established. Looking at the values of 
compounds 1b, 1g, 2b, 4b, 4c, 4d, 4g, 6b, 6g, 7b and 9b, it can be said that the insertion 
of a halogen moiety, increases the anti-tubercular activity. Taking into account the 
biological values reported in Table 1, it can be concluded that the insertion of a 
electron-withdrawing moiety, especially that of chlorine atom, is an essential 
requirement for the anti-tubercular activity, as previously established by our 
group.[21,22] 
With the aim of corroborating previous preliminary structure-activity 
relationship observed by our group and identifying the most suitable length for the 
aliphatic chain between the carboxamide group and the aromatic ring, three series of 
compounds (Series 1, 2 and 3) were prepared. Comparing the biological values shown 
by these compounds, it can be said that the preferred length for the aliphatic chain is one 
 methylene group. This data corroborates the hypothesis established in a previous report 
on analogue structures published by our group.[22] 
In previous investigations carried out by our group, three series of 1,4-di-N-
oxide-quinoxaline-2-carboxylic acid aryl amide derivatives were synthesized, 
containing a methyl moiety in position 3.[21,22] To further explore the SAR of these 
types of compounds, a phenyl group was substituted in position 3 of the quinoxaline 
ring (Series 1, 2 and 3) and reported in this paper. This modification led to a reduction 
of the anti-tubercular activity as can be observed by comparing the biological values of 
compounds from Series 1, 2 and 3 with their analogues containing a methyl group in 
position 3, described in previous reports.[21,22] 
Taking into account the biological values of the structures which present a 
phenyl group substituted in position 3 and the compounds with a methyl group in this 
position, [22] we decided to keep the methyl moiety in position 3 and modify the 
substitution on the aromatic ring. Different substituents were introduced on para 
position of the phenyl ring considering chloro, bromo or trifluoromethyl moiety as 
electron-withdrawing groups and methyl as electron-releasing group (Series 4, 5, 6, 7). 
In this fragment of the structure other substituents as byphenyl or a benzodioxol have 
been considered (Series 8, 9). Taking into account the biological values showed by 
these derivatives, it can be said that the insertion of a substituent on para position of the 
phenyl group did not improve the anti-tubercular activity suggesting that the most 
suitable aromatic ring is the un-substituted phenyl. 
5. Conclusions 
Forty-three new 1,4-di-N-oxide-quinoxaline-2-carboxylic acid aryl amide 
derivatives were synthesized using a variation of the Beirut reaction. All of the 
compounds were evaluated against M.Tbc. H37Rv stain; thirteen were active in the 
primary screening, showing an IC90≤10µg/mL, and were then moved on to the 
secondary screening level. Two of the compounds were active at this level, showing a 
SI≥10. 
Taking into account the biological values obtained, it can be said that the lead 
general structure for developing new anti-tubercular agents should consider the 1,4-di-
N-oxide quinoxaline ring with a carboxamide functionalized on position 2 and a methyl 
moiety on position 3. The most suitable substituent on positions 6 or/and 7 should be an 
electron-withdrawing group and a methyl moiety on position 3. With regard to the 
linker and the aromatic ring attached to it, one methylene group and an unsubstituted 
phenyl ring are considered to be the most appropriate substituents. 
6. Experimental protocols 
 6.1. Chemistry 
6.1.1. General remarks 
All of the synthesized compounds were chemically characterized by thin layer 
chromatography (TLC), infrared (IR), proton nuclear magnetic resonance (1H-NMR) 
and elemental microanalyses (CHN). 
Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG., 
Düren, Germany) was used for TLC, and Silica gel 60 (0.040-0.063 mm, Merck) was 
used for Conventional Flash Column Chromatography. Flash Column Chromatography 
was developed on a CombiFlash Rf (TELEDYNE ISCO, Lincoln, USA) instrument 
with Silica RediSep Rf columns. The 1H NMR spectra were recorded on a Bruker 400 
Ultrashield instrument (400 MHz), using TMS as internal standard and with DMSO-d6 
as solvent; the chemical shifts are reported in ppm (δ) and coupling constant (J) values 
are given in Hertz (Hz). Signal multiplicities are represented by: s (singlet), bs (broad 
singlet), d (doublet), dd (double doublet), ddd (double double doblet), t (triplet), tt 
(triple triplet) and m (multiplet). The IR spectra were recorded on a Nicolet Nexus FTIR 
(Thermo, Madison, USA) in KBr pellets. Elemental microanalyses were obtained on a 
CHN-900 Elemental Analyzer (Leco, Tres Cantos, Spain) from vacuum-dried samples. 
The analytical results for C, H and N, were within ± 0.4 of the theoretical values. 
Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-
Aldrich Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen 
Pharmaceuticalaan, Geel, Belgium) and Lancaster (Bischheim-Strasbourg, France). 
6.1.2. General procedure of the synthesis of 3-oxo-N-benzyl-3-phenylpropanamide (2). 
Acetic acid (5.0 mmol) and phenylglyoxal were diluted in diethyl ether (25 mL) 
under N2 atmosphere. Once dissolved, the benzylisocyanide (5.0 mmol) was added 
dropwise and the reaction mixture was stirred at room temperature for 72 hours. The 
residue obtained was filtered and washed with isopropanol. The solid was dissolved in 
methanol (32.0 mL) and added dropwise to a solution of Zn dust (8.0 mmol) in 
saturated aqueous NH4Cl (8.0 mL) previously activated in a sonication bath for 5 
minutes. The mixture was stirred at room temperature for 30 minutes and filtered in 
order to eliminate the Zn. Water (100 mL) was added to the mixture and the solid 
obtained was filtered and washed with water. The solid was used without further 
purification.[26] 
6.1.2.1. 3-oxo-N-benzyl-3-phenylpropanamide (2). Yield: 25%. IR (KBr): 3290 (m, N-
H); 3060 (w, arC-H); 1687 (s, C=O ketone); 1635 (s, C=O amide). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 8.66 (bs, 1H, NH); 7.99 (d, 2H, H2+H6-phCO, J2-3’= 7.2 Hz); 7.66-7.52 
 (m, 3H, H3-H5-phCO); 7.37-7.25 (m, 5H, H2-H6-phCH2); 4.32 (d, 2H, CH2-NH, JCH2-NH= 
5.9 Hz); 3.92 (s, 2H, CO-CH2-CO). 
6.1.3. General procedure of the synthesis of 3-oxo-N-(2-phenylethyl)-3-phenyl 
propanamide (3). 
Ethyl benzoylacetate (6.0 mmol), 2-phenethylamine (15.0 mmol) and 2-
hydroxypyridine (6.0 mmol) were refluxed at 130ºC under N2 atmosphere for 48 hours. 
The mixture reaction was dissolved in dichloromethane and quenched with water. The 
organic phase was dried with anhydrous sodium sulphate and filtered. The solvent was 
removed in vacuo and precipitated with cold isopropanol in order to obtain a white 
solid. The solid was used without further purification. [27] 
6.1.3.1.  3-oxo-N-(2-phenylethyl)-3-phenylpropanamide (3). Yield: 62%. IR (KBr): 
3336 (s, N-H); 3032 (w, arC-H); 1614 (s, C=O). 1H NMR (400 MHz, DMSO-d6) δ ppm: 
9.01 (bs, 1H, NH); 7.43-7.35 (m, 2H, H2+H6-phCO); 7.30-7.25 (m, 2H, H3+H5-phCO); 
7.24-7.14 (m, 5H, H4-phCO+H2+3+5+6-phCH2); 7.05-7.03 (m, 1H, H4-phCH2); 3.82 (s, 2H, CO-
CH2-CO); 3.30-3.21 (m, 2H, CH2-NH); 3.08-2.67 (m, 2H, CH2-ph). 
6.1.5. General procedure of the synthesis of 3-oxobutanamide derivatives (4-9) 
The corresponding aryl amines (20.0 mmol) were diluted in methanol (10 mL) 
under N2 atmosphere and cooled in an ice bath until 0º C. Next, diketene (25.0 mmol) 
was added dropwise and the reaction was stirred for 1-3 hours. The residue obtained 
was precipitated with cold diethyl ether and filtered in order to obtain a red-brown solid. 
The compound was used without further purification.[28] 
6.1.4.1. 3-oxo-N-(p-(trifluoromethyl)benzyl)butanamide (4). Yield: 84%. IR (KBr): 
3259 (m, N-H); 3090 (w, arC-H); 1716 (s, C=O ketone); 1644 (s, C=O amide); 1106 (m, arC-
CF3); 1111 (s, arC-CF3); 1069 (m, arC-CF3). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.64 
(t, 1H, NH, JNH-CH2= 5.5 Hz); 7.70 (d, 2H, H3’+H5’, J3’-2’= 7.9 Hz); 7.50 (d, 2H, 
H2’+H6’); 4.38 (d, 2H, CH2-NH); 3.41 (s, 2H, CO-CH2-CO); 2.16 (s, 3H, CH3-CO). 
6.1.4.2. 3-oxo-N-(p-chlorobenzyl)butanamide (5). Yield: 59%. IR (KBr): 3253 (s, N-
H); 3085 (m, arC-H); 1714 (s, C=O ketone); 1642 (s, C=O amide). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 8.55 (bs, 1H, NH); 7.39 (dd, 2H, H3’+H5’, J3’-2’= 8.5 Hz, J3’-Cl= 1.9 
Hz); 7.30 (d, 2H, H2’+H6’); 4.28 (d, 2H, CH2-NH, JCH2-NH= 5.9 Hz); 3.38 (s, 2H, CO-
CH2-CO); 2.15 (s, 3H, CH3-CO). 
6.1.4.3. 3-oxo-N-(p-bromobenzyl)butanamide (6). Yield: 57%. IR (KBr): 3253 (s, N-
H); 3085 (m, arC-H); 1714 (s, C=O ketone); 1642 (s, C=O amide); 1015 (m, arC-Br). 1H NMR 
(400 MHz, DMSO-d6) δ ppm: 8.55 (bs, 1H, NH); 7.52 (d, 2H, H3’+H5’, J3’-2’= 8.2 Hz); 
7.24 (d, 2H, H2’+H6’); 4.26 (d, 2H, CH2-NH, JCH2-NH= 5.5 Hz); 3.38 (s, 2H, CO-CH2-
CO); 2.15 (s, 3H, CH3-CO). 
 6.1.4.4. 3-oxo-N-(p-methylbenzyl)butanamide (7). Yield: 40%. IR (KBr): 3254 (m, N-
H); 3088 (m, arC-H); 1715 (m, C=O ketone); 1641 (s, C=O amide). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 8.47 (t, 1H, NH, JNH-CH2= 5.8 Hz); 7.20-7.10 (m, 4H, 
H2’+H3’+H5’+H6’); 4.24 (d, 2H, CH2-NH); 3.36 (s, 2H, CO-CH2-CO); 2.28 (s, 3H, 
CH3-ph); 2.15 (s, 3H, CH3-CO). 
6.1.4.5 N-(2,2-diphenylethyl)-3-oxobutanamide (8). Yield: 32%. IR (KBr): 3276 (s, 
N-H); 3020 (w, arC-H); 1710 (m, C=O ketone); 1668 (s, C=O amide). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 8.14 (t, 1H, NH, JNH-CH2= 5.6 Hz); 7.34-7.24 (m, 10H, 2ph); 4.19 (t, 
1H, CH, JCH-CH2= 7.9 Hz); 3.73 (dd, 2H, CH2-NH); 3.19 (s, 2H, CO-CH2-CO); 1.96 (s, 
3H, CH3-CO). 
6.1.4.6. N-(benzo[d][1,3]dioxol-5-ylmethyl)-3-oxobutanamide (9). Yield: 33%. IR 
(KBr): 3290 (m, N-H); 3064 (w, arC-H); 1758 (m, C=O ketone); 1615 (s, C=O amide); 1241 
(m, C=O). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.50 (t, 1H, NH, JNH-CH2= 5.6 Hz); 
7.02 (bs, 1H, H2’); 6.91 (bs, 2H, H5’+H6’); 6.01 (s, 2H, O-CH2-O); 4.27 (d, 2H, CH2-
NH); 3.37 (s, 2H, CO-CH2-CO); 2.15 (s, 3H, CH3-CO). 
6.1.5. General procedure of the synthesis of 1,4-di-N-oxide-quinoxaline-2-carboxylic 
acid aryl amide derivatives (Series 1-9) 
The appropriate BFX (1.0 mmol) and the corresponding β-ketoamide (1.2 mmol) 
were dissolved in a minimum amount of methanol. Next, calcium chloride (0.1 mmol) 
and ethanolamine (5 drops) were added as catalysts.[22,23] The mixture reaction was 
stirred at room temperature from 1 to 48 hours, depending on the BFX substituents 
used; it was then filtered and washed with cold diethyl ether. The solid was dissolved in 
dichloromethane and quenched with water. The organic phase was dried with anhydrous 
sodium sulphate and filtered. The solvent was removed in vacuo and precipitated with 
cold diethyl ether in order to obtain a yellow solid. The solid was purified by column 
chromatography, if necessary. 
6.1.5.1. 3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-oxide (1a). 
Yield: 17%. IR (KBr): 3256 (w, NH); 3077 (w, arC-H); 1693 (s, C=O); 1348 (s, N+O-). 
1H NMR (400 MHz, DMSO-d6) δ ppm: 10.80 (s, 1H, NH); 8.60-8.56 (m, 2H, H5+H8); 
8.10-8.07 (m, 2H, H6+H7); 7.62-7.60 (m, 2H, H2+H6-ph-QX); 7.49-7.47 (m; 3H, H3-H5-
ph-QX); 7.39 (dd, 2H, H2+H6-ph-NH, J2-3= 8.5 Hz, J2-4=1.0 Hz); 7.33-7.28 (m, 2H, 
H3+H5-ph-NH); 7.10 (tt, 1H, H4-ph-NH, J4-3= 7.2 Hz). Anal. Calcd. for C21H15N3O3: C, 
70.58%; H, 4.23%; N, 11.76%. Found: C, 70.72%; H, 4.48%; N, 11.99%. 
6.1.5.2. 7-chloro-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-oxide 
(1b). Yield: 18%. IR (KBr): 3256 (w, NH); 3058 (w, arC-H); 1686 (s, C=O); 1330 (s, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.82 (s, 1H, NH); 8.57-8.56 (m; 2H, 
 H5+H8); 8.11 (dd, 1H, H6, J6-5=9.0 Hz, J6-8=1.7 Hz); 7.61-7.59 (m, 2H, H2+H6-ph-QX); 
7.49-7.48 (m, 3H, H3-H5-ph-QX); 7.38 (d, 2H, H2+H6-ph-NH, J2-3= 7.9 Hz); 7.31 (t, 2H, 
H3+H5-ph-NH, J3-4= 7.9 Hz); 7.11 (t, 1H, H4-ph-NH). Anal. Calcd. for C21H14ClN3O3: C, 
64.38%; H, 3.60%; N, 10.72%. Found: C, 64.30%; H, 3.96%; N, 10.48%. 
6.1.5.3. 7-fluoro-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-oxide 
(1c). Yield: 17%. IR (KBr): 3244 (m, NH); 3058 (w, arC-H); 1658 (s, C=O); 1339 (s, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.83 (s, 1H, NH); 8.66-8.62 (m, 1H, 
H5); 8.34-8.32 (m, 1H, H8); 8.02-7.98 (m, 1H, H6); 7.60-7.59 (m, 2H, H2+H6-ph-QX); 
7.49-7.47 (m, 3H, H3-H5-ph-QX); 7.39-7.37 (m, 2H, H2+H6-ph-NH); 7.32-7.28 (m, 2H, 
H3+H5-ph-NH); 7.12-7.09 (m, 1H, H4-ph-NH). Anal. Calcd. for C21H14FN3O3: C, 67.20%; 
H, 3.76%; N, 11.20%. Found: C, 66.85%; H, 3.95%; N, 11.00%. 
6.1.5.4. 7-trifluoromethyl-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-
N-oxide (1d). Yield: 18%. IR (KBr): 3250 (w, NH); 3058 (w, arC-H); 1686 (s, C=O); 
1345 (s, N+O-); 1140 (s, arC-CF3). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.82 (s, 1H, 
NH); 8.83 (s, 1H, H8); 8.77 (d, 1H, H5, J5-6= 9.0 Hz); 8.39 (dd, 1H, H6, J6-8= 1.6 Hz); 
7.64-7.62 (m, 2H, H2+H6-ph-QX); 7.51-7.49 (m, 3H, H3-H5-ph-QX); 7.39-7.37 (m, 2H, 
H2+H6-ph-NH); 7.33-7.29 (m, 2H, H3+H5-ph-NH); 7.13-7.10 (m, 1H, H4-ph-NH). Anal. 
Calcd. for C22H14F3N3O3: C, 62.12%; H, 3.32%; N, 9.88%. Found: C, 61.83%; H, 
3.37%; N, 9.58%. 
6.1.5.5. 7-methyl-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-oxide 
(1e). Yield: 9%. IR (KBr): 3256 (w, NH); 3064 (w, arC-H); 1686 (s, C=O); 1335 (s, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.80 (s, 1H, NH); 8.47 (d, 1H, H5, J5-6= 
8.8 Hz); 8.41-8.35 (m, 1H, H8); 7.91 (dd, 1H, H6, J6-8= 1.2 Hz); 7.63-7.58 (m, 2H, 
H2+H6-ph-QX); 7.51-7.44 (m, 3H, H3-H5-ph-QX); 7.41-7.36 (m, 2H, H2+H6-ph-NH); 
7.33-7.27 (m, 2H, H3+H5-ph-NH); 7.13-7.07 (m, 1H, H4-ph-NH); 2.65 (s, 3H, CH3). 
Anal. Calcd. for C22H17N3O3: C, 71.15%; H, 4.61%; N, 11.31%. Found: C, 71.05%; H, 
4.80%; N, 11.01%. 
6.1.5.6. 7-methoxy-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-oxide 
(1f). Yield: 77%. IR (KBr): 3250 (m, NH); 3077 (m, arC-H); 1685 (s, C=O); 1335 (s, 
N+O-); 1243 (s, C-O-C). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.81 (s, 1H, NH); 8.48 
(d, 1H, H5, J5-6= 9.5 Hz); 7.87 (d, 1H, H8, J8-6= 2.7 Hz); 7.68 (dd, 1H, H6); 7.61-7.58 
(m, 2H, H2+H6-ph-QX); 7.48-7.46 (m, 3H, H3-H5-ph-QX); 7.38 (dd, 2H, H2+H6-ph-NH, 
J2-3= 8.5 Hz, J2-4= 1,1 Hz); 7.32-7.28 (m, 2H, H3+H5-ph-NH); 7.10 (tt, 1H, H4-ph-NH, J4-
3=7.3 Hz); 4.04 (s, 3H, OCH3). Anal. Calcd. for C22H17N3O4: C, 68.21%; H, 4.42%; N, 
10.85%. Found: C, 67.89%; H, 4.42%; N, 10.89%. 
 6.1.5.7. 6,7-dichloro-3-phenylquinoxaline-2-carboxylic acid phenylamide 1,4-di-N-
oxide (1g). Yield: 46%. IR (KBr): 3308 (m,NH); 3071 (m,arC-H); 1666 (s, C=O); 1332 
(s, N+O-); 1313 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 10.88 (s, 1H, NH); 
8.76 (s, 1H, H5); 8.74 (s, 1H, H8); 7.61-7.59 (m, 2H, H2+H6-ph-QX); 7.51-7.48 (m, 3H, 
H3-H5-ph-QX); 7.38 (dd, 2H, H2+H6-ph-NH, J2-3= 8.5 Hz, J2-4= 1.0 Hz); 7.33-7.29 (m, 
2H, H3+H5-ph-NH); 7.11 (tt, 1H, H4-ph-NH, J4-3= 7.8 Hz). Anal. Calcd. for 
C21H13Cl2N3O3.1/2H2O: C, 57.89%; H, 3.22%; N, 9.65%. Found: C, 57.56%; H, 2.91%; 
N, 9.54%. 
6.1.5.8. 3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-oxide (2a). 
Yield: 15%. IR (KBr): 3302 (m,NH); 3085 (w, arC-H); 1673 (s, C=O); 1348 (s, N+O-); 
1339 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.12 (t, 1H, NH, JNH-CH2= 5.8 
Hz); 8.58-8.53 (m, 2H, H5+H8); 8.06-8.04 (m, 2H, H6+H7); 7.57-7.56 (m, 3H, H3-H5-
ph-QX); 7.51-7.49 (m, 2H, H2+H6-ph-QX); 7.22-7.21 (m, 3H, H3-H5-ph-CH2); 6.90-6.87 
(m, 2H, H2+H6-ph-CH2); 4.28 (d, 2H, CH2). Anal. Calcd. for C22H17N3O3: C, 71.15%; H, 
4.61%; N, 11.31%. Found: C, 71.02%; H, 4.50%; N, 10.94%. 
6.1.5.9. 7-chloro-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-oxide 
(2b). Yield: 22%. IR (KBr): 3286 (m, NH); 3094 (w, arC-H); 1649 (s, C=O); 1331 (m, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.12 (t, 1H, NH, JNH-CH2= 5.9 Hz); 8.56-
8.54 (m, 1H, H5), 8.50 (bs; 1H, H8); 8.08 (dd, 1H, H6, J6-5= 9.2 Hz, J6-8= 2.2 Hz); 7.58-
7.49 (m, 5H, H2-H6-ph-QX); 7.21-7.20 (m, 3H, H3-H5-ph-CH2); 6.89-6.87 (m, 2H, 
H2+H6-ph-CH2); 4.28 (d, 2H, CH2). Anal. Calcd. for C22H16ClN3O3: C, 65.10%; H, 
3.97%; N, 10.35%. Found: C, 65.41%; H, 3.97%; N, 10.16%. 
6.1.5.10. 7-fluoro-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-oxide 
(2c). Yield: 22%. IR (KBr): 3312 (m, NH); 3059 (w, arC-H); 1673 (s, C=O); 1335 (m, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.14 (t, 1H, NH, JNH-CH2= 5.7 Hz); 8.62-
8.59 (m, 1H, H5); 8.33-8.30 (m, 1H, H8); 7.99-7.94 (m, 1H, H6); 7.94-7.49 (m, 5H, H2-
H6-ph-QX); 7.21-7.20 (m, 3H, H3-H5-ph-CH2); 6.90-6.88 (m, 2H, H2+H6-ph-CH2); 4.28 (d, 
2H, CH2). Anal. Calcd. for C22H16FN3O3.1/2H2O: C, 66.26%; H, 4.27%; N, 10.54%. 
Found: C, 66.56%; H, 4.04%; N, 10.17%. 
6.1.5.11. 7-trifluoromethyl-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-
N-oxide (2d). Yield: 6%. IR (KBr): 3287 (m, NH); 3093 (w, arC-H); 1647 (s, C=O); 
1350 (s, N+O-); 1319 (s,N+O-); 1171 (s, ar-CF3); 1125 (s, ar-CF3). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 9.15-9.10 (m, 1H, NH); 8.81-8.77 (m, 1H, H5); 8.44-8.28 (m, 2H, 
H8+H6); 7.59-7.51 (m, 5H, H2-H6-ph-QX); 7.25-7.21 (m, 5H, H2-H6-ph-CH2); 4.29 (d, 
2H, CH2, JCH2-NH=5.9 Hz). Anal. Calcd. for C23H16F3N3O3: C, 62.87%; H, 3.67%; N, 
9.56%. Found: C, 63.03%; H, 3.96%; N, 9.36%. 
 6.1.5.12. 7-methyl-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-oxide 
(2e). Yield: 36%. IR (KBr): 3224 (m, NH); 3058 (w, arC-H); 1682 (s, C=O); 1355 
(s,N+O-); 1314 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.13 (t, 1H, NH, JNH-
CH2= 5.9 Hz); 8.43 (d, 1H, H5, J5-6= 8.8 Hz); 8.37 (s, 1H, H8); 7.87 (dd, 1H, H6, J6-8= 1.8 
Hz); 7.59-7.55 (m, 3H, H3-H5-ph-QX); 7.51-7.48 (m, 2H, H2+H6-ph-QX); 7.21-7.19 (m, 
3H, H3-H5-ph-CH2); 6.90-6.87 (m, 2H, H2+H6-ph-CH2); 4.28 (d, 2H, CH2). Anal. Calcd. 
for C23H19N3O3.1/2H2O: C, 69.97%; H, 5.07%; N, 10.65%. Found: C, 70.35%; H, 
5.03%; N, 10.65%. 
6.1.5.13. 6-methoxy-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-oxide 
(2f). Yield: 35%. IR (KBr): 3262 (m, NH); 3080 (w, arC-H); 1689 (s, C=O); 1352 (s, 
N+O-); 1328 (s,N+O-); 1256 (s, C-O-C). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.14 (t, 
1H, NH, JNH-CH2= 5.9 Hz); 8.44 (d, 1H, H5, J5-6= 9.5 Hz); 7.86 (d, 1H, H8, J8-6= 2.7 Hz); 
7.65 (dd, 1H, H6); 7.58-7.54 (m, 3H, H3-H5-ph-QX); 7.51-7.48 (m, 2H, H2+H6-ph-QX); 
7.22-7.20 (m, 3H, H3-H5-ph-CH2); 6.93-6.90 (m, 2H, H2+H6-ph-CH2); 4.27 (d, 2H, CH2); 
4.03 (s, 3H, OCH3). Anal. Calcd. for C23H19N3O4: C, 68.82%; H, 4.77%; N, 10.47%. 
Found: C, 68.94%; H, 4.87%; N, 10.26%. 
6.1.5.14. 6,7-dichloro-3-phenylquinoxaline-2-carboxylic acid benzylamide 1,4-di-N-
oxide (2g). Yield: 8%. IR (KBr): 3280 (m, NH); 3062 (w, arC-H); 1649 (s, C=O); 1327 
(s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.15 (t, 1H, NH, JNH-CH2= 5.9Hz); 
8.75 (s, 1H, H5); 8.70 (s, 1H, H8); 7.50-7.48 (m, 5H, H2-H6-ph-QX); 7.22-7.20 (m, 3H, 
H3-H5-ph-CH2); 6.90-6.88 (m, 2H, H2+H6-ph-CH2); 4.27 (d, 2H, CH2). Anal. Calcd. for 
C22H15Cl2N3O3: C, 60.02%; H, 3.43%; N, 9.54%. Found: C, 60.07%; H, 3.56%; N, 
9.46%. 
6.1.5.15. 3-phenylquinoxaline-2-carboxylic acid (2-phenylethyl)amide 1,4-di-N-oxide 
(3a). Yield: 10%. IR (KBr): 3269 (w, NH); 3078 (w, arC-H); 1679 (s, C=O); 1328 (s, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.75 (t, 1H, NH, JNH-CH2= 5.7Hz); 8.55-
8.52 (m, 2H, H5+H8); 8.05-8.03 (m, 2H, H6+H7); 7.57-7.51 (m, 5H, H2-H6-ph-QX); 7.27 
(t, 2H, H3+H5-ph-CH2, J3-2=J3-4= 7.3 Hz); 7.20 (t, 1H, H4-ph-CH2); 7.09 (d, 2H, H2+H6-
ph-CH2); 3.27-3.21 (m, 2H, CH2-NH); 2.39 (t, 2H, CH2-ph, JCH2-CH2= 7.3Hz). Anal. 
Calcd. for C23H19N3O3: C, 71.68%; H, 4.97%; N, 10.90%. Found: C, 71.72%; H, 
5.22%; N, 10.88%. 
6.1.5.16. 7-chloro-3-phenylquinoxaline-2-carboxylic acid (2-phenylethyl)amide 1,4-di-
N-oxide (3b). Yield: 8%. IR (KBr): 3304 (w, NH); 3056 (wd, arC-H); 1668 (s, C=O); 
1330 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.75 (t, 1H, NH, JNH-CH2= 
5.6Hz); 8.54-8.52 (m, 2H, H5+H8); 8.07 (dd, H6, J6-5= 9.3 Hz, J6-8= 2.2 Hz); 7.56-7.51 
(m, 5H, H2-H6-ph-QX); 7.27 (t, 2H, H3+H5-ph-CH2, J3-2=J3-4= 7.3Hz); 7.19 (t, 1H, H4-ph-
 CH2); 7.09 (d, 2H, H2+H6-ph-CH2); 3.27-3.21 (m, 2H, CH2-NH); 2.39 (t, 2H, CH2-ph, 
JCH2-CH2= 7.4 Hz). Anal. Calcd. for C23H18ClN3O3: C, 65.80%; H, 4.32%; N, 10.01%. 
Found: C, 65.95%; H, 4.46%; N, 10.09%. 
6.1.5.17. 3-methylquinoxaline-2-carboxylic acid p-trifluoromethylbenzylamide 1,4-di-N-
oxide (4a). Yield: 21%. IR (KBr): 3205 (w, N-H); 3039 (w, arC-H); 1669 (s, C=O); 1325 
(s, N+O-); 1166 (m, arC-CF3); 1101 (m, arC-CF3); 1068 (m, arC-CF3). 1H NMR (400 MHz, 
DMSO-d6) δ ppm: 9.49 (t, 1H, NH, JNH-CH2= 5.9 Hz); 8.53-8.49 (m, 2H, H5+H8); 8.03-
7.96 (m, 2H, H6+H7); 7.77 (d, 2H, H3’+H5’, J3’-2’= 8.2 Hz); 7.70 (d, 2H, H2’+H6’); 4.67 
(d, 2H, CH2); 2.44 (s, 3H, CH3-C3). Anal. Calcd. for C18H14F3N3O3: C, 57.30%; H, 
3.74%; N, 11.14%. Found: C, 57.02%; H, 3.79%; N, 11.00%. 
6.1.5.18. 7-chloro-3-methylquinoxaline-2-carboxylic acid p-trifluoromethylbenzylamide 
1,4-di-N-oxide (4b). Yield: 37%. IR (KBr): 3277 (w, N-H); 3103 (w, arC-H); 1650 (m, 
C=O); 1328 (s, N+O-); 1161 (m, arC-CF3); 1109 (m, arC-CF3); 1072 (m, arC-CF3). 1H NMR 
(400 MHz, DMSO-d6) δ ppm: 9.49 (t, 1H, NH, JNH-CH2= 5.9 Hz); 8.50 (s, 2H, H5+H8); 
8.04 (dd, 1H, H6, J6-5= 9.1 Hz, J6-8= 2.3 Hz); 7.77 (d, 2H, H3’+H5’, J3’-2’= 8.1 Hz); 7.69 
(d, 2H, H2’+H6’); 4.66 (d, 2H, CH2); 2.43 (s, 3H, CH3-C3). Anal. Calcd. for 
C18H13ClF3N3O3: C, 52.51%; H, 3.18%; N, 10.20%. Found: C, 52.26%; H, 3.19%; N, 
9.95%. 
6.1.5.19. 7-fluoro-3-methylquinoxaline-2-carboxylic acid p-trifluoromethylbenzylamide 
1,4-di-N-oxide (4c). Yield: 51%. IR (KBr): 3212 (w, N-H); 3079 (w, arC-H); 1671 (m, 
C=O); 1327 (s, N+O-); 1167 (m, arC-CF3); 1101 (m, arC-CF3); 1065 (m, arC-CF3). 1H NMR 
(400 MHz, DMSO-d6) δ ppm: 9.50 (t, 1H, NH, JNH-CH2= 5.8 Hz); 8.58 (dd, 1H, H5, J5-6= 
9.5 Hz, J5-F= 5.1 Hz); 8.25 (dd, 1H, H8, J8-F= 8.8 Hz, J8-6= 2.4 Hz); 7.93 (ddd, 1H, H6, 
J6-F= 9.4 Hz); 7.77 (d, 2H, H3’+H5’, J3’-2’= 8.1 Hz); 7.69 (d, 2H, H2’+H6’); 4.67 (d, 2H, 
CH2); 2.43 (s, 3H, CH3-C3). Anal. Calcd. for C18H13F4N3O3: C, 54.69%; H, 3.31%; N, 
10.63%. Found: C, 54.64%; H, 3.30%; N, 10.36%. 
6.1.5.20. 3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid p-trifluoromethyl 
benzylamide 1,4-di-N-oxide (4d). Yield: 12%. IR (KBr): 3212 (w, N-H); 3064 (w, arC-
H); 1679 (s, C=O); 1326 (s, N+O-); 1168 (m, arC-CF3); 1143 (m, arC-CF3); 1111 (m, arC-
CF3); 1085 (m, arC-CF3). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.52 (t, 1H, NH, JNH-
CH2= 5.5 Hz); 8.76 (s, 1H, H8); 8.70 (d, 1H, H5, J5-6= 9.0 Hz); 8.29 (dd, 1H, H6, J6-8= 1.7 
Hz); 7.78 (d, 2H, H3’+H5’, J3’-2’ = 8.1 Hz); 7.70 (d, 2H, H2’+H6’); 4.68 (d, 2H, CH2); 
2.47 (s, 3H, CH3-C3). Anal. Calcd. for C19H13F6N3O3: C, 51.25%; H, 2.94%; N, 9.44%. 
Found: C, 51.26%; H, 2.74%; N, 9.34%. 
6.1.5.21. 3,7-dimethylquinoxaline-2-carboxylic acid p-trifluoromethylbenzylamide 1,4-
di-N-oxide (4e). Yield: 28%. IR (KBr): 3199 (w, N-H); 3032 (w, arC-H); 1669 (s, C=O); 
 1325 (s, N+O-); 1165 (m, arC-CF3); 1100 (m, arC-CF3); 1167 (m, arC-CF3). 1H NMR (400 
MHz, DMSO-d6) δ ppm: 9.49 (t, 1H, NH, JNH-CH2= 5.5 Hz); 8.40 (d, 1H, H5, J5-6= 8.8 
Hz); 8.31 (s, 1H, H8); 7.84 (d, 1H, H6); 7.76 (d, 2H, H3’+H5’, J3’-2’= 8.2 Hz); 7.70 (d, 
2H, H2’+H6’); 4.66 (d, 2H, CH2); 2,59 (s, 3H, CH3-C7); 2.42 (s, 3H, CH3-C3). Anal. 
Calcd. for C19H16F3N3O3: C, 58.31%; H, 4.12%; N, 10.74%. Found: C, 58.05%; H, 
4.09%; N, 10.48%. 
6.1.5.22. 7-methoxy-3-methyl-quinoxaline-2-carboxylic acid p-trifluoromethylbenzyl 
amide 1,4-di-N-oxide (4f). Yield: 29%. IR (KBr): 3212 (w, N-H); 3040 (w, arC-H); 1679 
(m, C=O); 1325 (s, N+O-); 1169 (m, arC-CF3); 1118 (m, arC-CF3); 1066 (m, arC-CF3). 1H 
NMR (400 MHz, DMSO-d6) δ ppm: 9.51 (t, 1H, NH, JNH-CH2= 5.6 Hz); 8.42 (d, 1H, H5, 
J5-6= 9.5 Hz); 7.81 (d, 1H, H8, J8-6= 2.60 Hz); 7.77 (d, 2H, H3’+H5’, J3’-2’= 8.1 Hz); 7.71 
(d, 2H, H2’+H6’); 7.61 (dd, 1H, H6); 4.66 (d, 2H, CH2); 4.00 (s, 3H, OCH3); 2,41 (s, 3H, 
CH3-C3). Anal. Calcd. for C19H16F3N3O4: C, 56.02%; H, 3.96%; N, 10.32%. Found: C, 
55.90%; H, 3.84%; N, 10.14%. 
6.1.5.23. 6,7-dichloro-3-methyl-quinoxaline-2-carboxylic acid p-trifluoromethylbenzyl 
amide 1,4-di-N-oxide (4g). Yield: 12%. IR (KBr): 3237 (w, N-H); 3071 (w, arC-H); 
1670 (m, C=O); 1323 (s, N+O-); 1169 (m, arC-CF3); 1109 (m, arC-CF3); 1069 (m, arC-CF3). 
1H NMR (400 MHz, DMSO-d6) δ ppm: 9.51 (t, 1H, NH, JNH-CH2= 5.8 Hz); 8.69 (s, 1H, 
H5); 8.68 (s, 1H, H8); 7.76 (d, 2H, H3’+H5’, J3’-2’= 8.4 Hz); 7.68 (d, 2H, H2’+H6’); 4.66 
(d, 2H, CH2); 2.43 (s, 3H, CH3-C3). Anal. Calcd. for C18H12Cl2F3N3O3: C, 48.45%; H, 
2.71%; N, 9.42%. Found: C, 48.75%; H, 2.82%; N, 9.44%. 
6.1.5.24. 3-methylquinoxaline-2-carboxylic acid p-chlorobenzylamide 1,4-di-N-oxide 
(5a). Yield: 47%. IR (KBr): 3192 (w, N-H); 3071 (w, arC-H); 1675 (s, C=O); 1327 (s, 
N+O-); 1082 (m, arC-Cl). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (t, 1H, NH, JNH-
CH2= 5.8 Hz); 8.53-8.49 (m, 2H, H5+H8); 8.01-7.97 (m, 2H, H6+H7); 7.49 (d, 2H, 
H3’+H5’, J3’-2’= 8.5 Hz); 7.45 (d, 2H, H2’+H6’); 4.56 (d, 2H, CH2); 2.42 (s, 3H, CH3-C3). 
Anal. Calcd. for C17H14ClN3O3: C, 59.40%; H, 4.10%; N, 12.22%. Found: C, 59.14%; 
H, 4.10%; N, 12.58%. 
6.1.5.25. 7-chloro-3-methylquinoxaline-2-carboxylic acid p-chlorobenzylamide 1,4-di-
N-oxide (5b). Yield: 37%. IR (KBr): 3271 (w, N-H); 3103 (w, arC-H); 1650 (s, C=O); 
1326 (s, N+O-); 1073 (m, arC-Cl). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (t, 1H, 
NH, JNH-CH2= 5.7 Hz); 8.50 (d, 1H, H5, J5-6= 9.3 Hz); 8.49 (d, 1H, H8, J8-6= 2.0 Hz); 
8.04 (dd, 1H, H6); 7.48 (d, 2H, H3’+H5’, J3’-2’= 8.6 Hz); 7.45 (d, 2H, H2’+H6’); 4.55 (d, 
2H, CH2); 2.41 (s, 3H, CH3-C3). Anal. Calcd. for C17H13Cl2N3O3: C, 53.99%; H, 
3.46%; N, 11.11%. Found: C, 54.03%; H, 3.53%; N, 11.05%. 
 6.1.5.26. 3,7-dimethylquinoxaline-2-carboxylic acid p-chlorobenzylamide 1,4-di-N-
oxide (5e). Yield: 21%. IR (KBr): 3250 (w, N-H); 3064 (w, arC-H); 1670 (s, C=O); 1322 
(s, N+O-); 1068 (m, arC-Cl). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (t, 1H, NH, 
JNH-CH2= 5.5 Hz); 8.40 (d, H5, J5-6= 8.8 Hz); 8.31 (s, 1H, H8); 7.83 (dd, 1H, H6, J6-8= 1.5 
Hz); 7.49 (dd, 2H, H3’+H5’, J3’-2’= 8.5 Hz, J3’-Cl= 1.3 Hz); 7.45 (dd, 2H, H2’+H6’, J2’-Cl= 
1.1 Hz); 4.55 (d, 2H, CH2); 2.59 (s, 3H, CH3-C7); 2.40 (s, 3H, CH3-C3). Anal. Calcd. 
for C18H16ClN3O3: C, 60.43%; H, 4.51%; N, 11.74%. Found: C, 60.08%; H, 4.46%; N, 
11.51%. 
6.1.5.27. 6,7-dichloro-3-methylquinoxaline-2-carboxylic acid p-chlorobenzylamide 1,4-
di-N-oxide (5g). Yield: 11%. IR (KBr): 3243 (w, N-H); 3071 (w, arC-H); 1671 (s, C=O); 
1321 (s, N+O-); 1066 (m, arC-Cl). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.43 (t, 1H, 
NH, JNH-CH2= 5.9 Hz); 8.69 (d, 1H, H5, J5-8= 0.5 Hz); 8.68 (d, 1H, H8); 7.48 (d, 2H, 
H3’+H5’, J3’-2’= 8.8 Hz); 7.45 (d, 2H, H2’+H6’); 4.55 (d, CH2); 2.41 (s, 3H, CH3-C3). 
Anal. Calcd. for C17H12Cl3N3O3: C, 49.48%; H, 2.93%; N, 10.18%. Found: C, 49.76%; 
H, 2.98%; N, 10.12%. 
6.1.5.28. 3-methylquinoxaline-2-carboxylic acid p-bromobenzylamide 1,4-di-N-oxide 
(6a). Yield: 7%. IR (KBr): 3271 (w, N-H); 3090 (w, arC-H); 1677 (s, C=O); 1331 (s, 
N+O-); 1073 (m, arC-Br). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (t, 1H, NH, JNH-
CH2=5.8 Hz); 8.52-8.49 (m, 2H, H5+H8); 8.03-7.96 (m, 2H, H6+H7); 7.59 (d, 2H, 
H3’+H5’, JH3’-H2’= 8.3 Hz); 7.43 (d, 2H, H2’+H6’); 4.54 (d, 2H, CH2); 2.42(s, 3H, CH3-
C3). Anal. Calcd. for C17H14BrN3O3: C, 52.60%; H, 3.63%; N, 10.82%. Found: C, 
52.23%; H, 3.55%; N, 10.43%. 
6.1.5.29. 7-chloro-3-methylquinoxaline-2-carboxylic acid p-bromobenzylamide 1,4-di-
N-oxide (6b). Yield: 14%. IR (KBr): 3237 (w, N-H); 3064 (w, arC-H); 1670 (s, C=O); 
1325 (s, N+O-); 1071 (m, arC-Br). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (bs, 1H, 
NH); 8.50 (d, 1H, H5, J5-6=9.3 Hz); 8.49 (d, 1H, H8, J8-6=2.4 Hz); 8.04 (dd, 1H, H6); 
7.59 (d, 2H, H3’+H5’, J3’-2’= 8.4 Hz); 7.42 (d, 2H, H2’+H6’); 4.53 (d, 2H, CH2, JCH2-
NH=5.8 Hz); 2.41 (s, 3H, CH3-C3). Anal. Calcd. for C17H13BrClN3O3: C, 48.31%; H, 
3.10%; N, 9.94%. Found: C, 48.30%; H, 3.00%; N, 9.64%. 
6.1.5.30. 3,7-dimethylquinoxaline-2-carboxylic acid p-bromobenzylamide 1,4-di-N-
oxide (6e). Yield: 27%. IR (KBr): 3205 (w, N-H); 3058 (w, arC-H); 1667 (s, C=O); 1327 
(s, N+O-); 1068 (m, arC-Br). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.40 (bs, 1H, NH); 
8.40 (d, 1H, H5, J5-6= 8.8 Hz); 8.31 (s, 1H, H8); 7.83 (dd, 1H, H6, J6-8= 1.3 Hz); 7.58 (d, 
2H, H3’+H5’, J3’-2’= 8.5 Hz); 7.43 (d, 2H, H2’+H6’); 4.53 (d, 2H, CH2, JCH2-NH= 5.9 Hz); 
2.59 (s, 3H, CH3-C7); 2.40 (s, 3H, CH3-C3). Anal. Calcd. for C18H16BrN3O3: C, 53.75%; 
H, 4.01%; N, 10.45%. Found: C, 53.41%; H, 3.86%; N, 10.07%. 
 6.1.5.31. 6,7-dichloro-3-methylquinoxaline-2-carboxylic acid p-bromobenzylamide 1,4-
di-N-oxide (6g). Yield: 14%. IR (KBr): 3237 (w, N-H); 3066 (w, arC-H); 1670 (s, C=O); 
1320 (s, N+O-); 1067 (m, arC-Br). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.43 (t, 1H, 
NH, JNH-CH2= 5.9 Hz); 8.69 (s, 1H, H5); 8.68 (s, 1H, H8); 7.58 (d, 2H, H3’+H5’, J3’-2’= 
8.3 Hz); 7.41 (d, 2H, H2’+H6’); 4.53 (d, 2H, CH2); 2.41 (s, 3H, CH3-C3). Anal. Calcd. 
for C17H12BrCl2N3O3: C, 44.67%; H, 2.65%; N, 9.19%. Found: C, 44.33%; H, 2.56%; 
N, 8.92%. 
6.1.5.32. 3-methylquinoxaline-2-carboxylic acid p-methylbenzylamide 1,4-di-N-oxide 
(7a). Yield: 61%. IR (KBr): 3224 (w, N-H); 3045 (w, arC-H); 1671 (s, C=O); 1336 (s, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.30 (t, 1H, NH, JNH-CH2= 5.8 Hz); 8.52-
8.49 (m, 2H, H5+H8); 8.02-7.97 (m, 2H, H6+H7); 7.33 (d, 2H, H2’+H6’, J2’-3’= 7.8 Hz); 
7.19 (d, 2H, H3’+H5’); 4.51 (d, 2H, CH2); 2.42 (s, 3H, CH3-C3); 2.30 (s, 3H, CH3-ph). 
Anal. Calcd. for C18H17N3O3: C, 66.86%; H, 5.30%; N, 13.00%. Found: C, 66.62%; H, 
5.28%; N, 12.78%. 
6.1.5.33. 7-chloro-3-methylquinoxaline-2-carboxylic acid p-methylbenzylamide 1,4-di-
N-oxide (7b). Yield: 35%. IR (KBr): 3259 (w, N-H); 3077 (w, arC-H); 1671 (s, C=O); 
1325 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.30 (t, 1H, NH, JNH-CH2= 5.9 
Hz); 8.50 (d, 1H, H5, J5-6= 9.1 Hz); 8.48 (s, 1H, H8); 8.03 (dd, 1H, H6, J6-8= 2.3 Hz); 
7.32 (d, 2H, H2’+H6’, J2’-3’= 7.9 Hz); 7.19 (d, 2H, H3’+H5’); 4.51 (d, 2H, CH2); 2.40 (s, 
3H, CH3-C3); 2.30 (s, 3H, CH3-ph). Anal. Calcd. for C18H16ClN3O3: C, 60.43%; H, 
4.51%; N, 11.74%. Found: C, 60.41%; H, 4.57%; N, 11.71%. 
6.1.5.34. 3,7-dimethylquinoxaline-2-carboxylic acid p-methylbenzylamide 1,4-di-N-
oxide (7e). Yield: 10%. IR (KBr): 3281 (m, N-H); 3065 (w, arC-H); 1650 (s, C=O); 1325 
(s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.31 (bs, 1H, NH); 8.39 (d, 1H, H5, 
J5-6= 8.8 Hz); 8.30 (s, 1H, H8); 7.83 (dd, 1H, H6, J6-8= 1.8 Hz); 7.33 (d, 2H, H2’+H6’, 
J2’-3’= 8.1 Hz); 7.19 (d, 2H, H3’+H5’); 4.50 (d, 2H, CH2, JCH2-NH= 5.8 Hz); 2.60 (s, 3H, 
CH3-C7); 2.40 (s, 3H, CH3-C3); 2.30 (s, 3H, CH3-ph). Anal. Calcd. for C19H19N3O3: C, 
67.64%; H, 5.68%; N, 12.45%. Found: C, 67.27%; H, 5.70%; N, 12.25%. 
6.1.5.35. 6,7-dichloro-3-methylquinoxaline-2-carboxylic acid p-methylbenzylamide 1,4-
di-N-oxide (7g). Yield: 12%. IR (KBr): 3270(m, N-H); 3045 (w, arC-H); 1649 (s, C=O); 
1359 (m, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.35 (t, 1H, NH, JNH-CH2= 5.3 
Hz); 8.62 (s, 1H, H5); 8.45 (s, 1H, H8); 7.32 (d, 2H, H2’+H6’, J2’-3’= 7.3 Hz); 7.19 (d, 
2H, H3’+H5’); 4.51 (d, 2H, CH2); 2.55(s, 3H, CH3-C3); 2.30 (s, 3H, CH3-ph). Anal. 
Calcd. for C18H15Cl2N3O3: C, 55.12%; H, 3.85%; N, 10.71%. Found: C, 55.37%; H, 
4.17%; N, 10.45%. 
 6.1.5.36. 3-methylquinoxaline-2-carboxylic acid 2,2-diphenylethylamide 1,4-di-N-oxide 
(8a). Yield: 8%. IR (KBr): 3237 (w, N-H); 3064 (w, arC-H); 1681 (s, C=O); 1339 (m, 
N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, NH, JNH-CH2= 5.7 Hz); 8.47-
8.42 (m, 2H, H5+H8); 7.99-7.92 (m, 2H, H6+H7); 7.41 (dd, 4H, 2H2’+2H6’, J2’-3’= 7.2 
Hz, J2’-4’=1.3 Hz); 7.35-7.31 (m, 4H, 2H3’+2H5’); 7.20 (tt, 2H, 2H4’, J4’-3’= 7.3 Hz); 4.32 
(t, 1H, CH, JCH-CH2= 8.0 Hz); 4.02 (dd, 2H, CH2); 1.97 (s, 3H, CH3-C3). Anal. Calcd. 
for C24H21N3O3: C, 72.17%; H, 5.30%; N, 10.52%. Found: C, 72.02%; H, 5.34%; N, 
10.29%. 
6.1.5.37. 7-chloro-3-methylquinoxaline-2-carboxylic acid 2,2-diphenylethylamide 1,4-
di-N-oxide (8b). Yield: 17%. IR (KBr): 3231 (w, N-H); 3058 (w, arC-H); 1679 (s, C=O); 
1326 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.88 (bs, 1H, NH); 8.45 (d, 1H, 
H5, J5-6= 9.2 Hz); 8.41 (d, 1H, H8, J8-6= 2.1 Hz); 8.00 (dd, 1H, H6); 7.40 (dd, 4H, 
2H2’+2H6’, J2’-3’= 7.8 Hz, J2’-4’=1.2 Hz); 7.35-7.30 (m, 4H, 2H3’+2H5’); 7.22 (tt, 2H, 
2H4’, J4’-3’=7.3 Hz); 4.32 (t, 1H, CH, JCH-CH2= 7.9 Hz); 4.03 (dd, 2H, CH2); 1.98 (s, 3H, 
CH3-C3). Anal. Calcd. for C24H20ClN3O3: C, 66.44%; H, 4.65%; N, 9.68%. Found: C, 
66.53%; H, 5.03%; N, 9.31%. 
6.1.5.38. 3,7-dimethylquinoxaline-2-carboxylic acid 2,2-diphenylethylamide 1,4-di-N-
oxide (8e). Yield: 11%. IR (KBr): 3223 (w, N-H); 3057 (w, arC-H); 1678 (s, C=O); 1328 
(s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.90 (bs, 1H, NH); 8.34 (d, 1H, H5, 
J5-6= 8.5 Hz); 8.23 (s, 1H, H8); 7.79 (dd, 1H, H6, J6-8=1.2 Hz); 7.40 (d, 4H, 2H2’+2H6’, 
J2’-3’= 7.5 Hz); 7.32 (t, 4H, 2H3’+2H5’, J3’-4’= 7.5Hz); 7.24-7.20 (m, 2H, 2H4’); 4.31 (t, 
1H, CH, JCH-CH2= 7.9 Hz); 4.02 (dd, 2H, CH2, JCH2-NH= 5.8 Hz); 2.57 (s, 3H, CH3-C7); 
1.95 (m, 3H, CH3-C3). Anal. Calcd. for C25H23N3O3: C, 72.62%; H, 5.61%; N, 10.16%. 
Found: C, 72.26%; H, 5.84%; N, 9.77%. 
6.1.5.39. 6,7-dichloro-3-methylquinoxaline-2-carboxylic acid 2,2-diphenylethylamide 
1,4-di-N-oxide (8g). Yield: 15%. IR (KBr): 3212 (w, N-H); 3083 (w, arC-H); 1676 (s, 
C=O); 1321 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.91 (t, 1H, NH, JNH-CH2= 
5.8 Hz); 8.63 (s, 1H, H5); 8.60 (s, 1H, H8); 7.40 (dd, 4H, 2H2’+2H6’, J2’-3’= 7.8 Hz, J2’-
4’= 1.3 Hz); 7.32 (dd, 4H, 2H3’+2H5’, J3’-4’= 7.4 Hz); 7.24 (tt, 2H, 2H4’); 4.32 (t, 1H, 
CH, JCH-CH2= 8.1 Hz); 4.02 (dd, 2H, CH2); 1.07 (s, 3H, CH3-C3). Anal. Calcd. for 
C24H19Cl2N3O3.1/2H2O: C, 60.33%; H, 4.22%; N, 8.79%. Found: C, 60.10%; H, 4.25%; 
N, 8.60%. 
6.1.5.40. 3-methylquinoxaline-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 
1,4-di-N-oxide (9a). Yield: 25%. IR (KBr): 3261 (m, N-H); 3077 (w, arC-H); 1642 (s, 
C=O); 1329 (m, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, NH, JNH-
CH2= 5.8 Hz); 8.52-8.38 (m, 2H, H5+H8); 8.02-7.95 (m, 2H, H6+H7); 7.03 (bs, 1H, H2’); 
 6.91 (bs, 2H, H5’+H6’); 6.01 (s, 2H, O-CH2-O); 4.47 (d, 2H, CH2); 2.42 (s, 3H, CH3-
C3). Anal. Calcd. for C18H15N3O5.1/2H2O: C, 59.61%; H, 4.41%; N, 11.59%. Found: C, 
59.72%; H, 4.32%; N, 11.56%. 
6.1.5.41. 7-chloro-3-methylquinoxaline-2-carboxylic acid (benzo[1,3]dioxol-5-yl 
methyl)amide 1,4-di-N-oxide (9b). Yield: 18%. IR (KBr): 3276 (w, N-H); 3090 (w, arC-
H); 1649 (s, C=O); 1326 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, 
NH, JNH-CH2= 5.6 Hz); 8.51-8.49 (m, 2H, H5+H8); 8.05-8.02 (m, 1H, H6); 7.02 (bs, 1H, 
H2’); 6.91 (bs, 2H, H5’+H6’); 6.01 (s, 2H, O-CH2-O); 4.46 (d, 2H, CH2); 2.40 (s, 3H, 
CH3-C3). Anal. Calcd. for C18H14ClN3O5: C, 55.75%; H, 3.64%; N, 10.84%. Found: C, 
55.50%; H, 3.46%; N, 10.68%. 
6.1.5.42. 3,7-dimethylquinoxaline-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl) 
amide 1,4-di-N-oxide (9e). Yield: 21%. IR (KBr): 3266 (w, N-H); 3071 (w, arC-H); 1649 
(s, C=O); 1325 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, NH, JNH-
CH2= 5.8 Hz); 8.39 (d, 1H, H5, J5-6= 8.8 Hz); 8.31 (s, 1H, H8); 7.83 (d, 1H, H6); 7.04 (bs, 
1H, H2’); 6.91 (bs, 2H, H5’+H6’); 6.02 (s, 2H, O-CH2-O); 4.47 (d, 2H, CH2); 2.59 (s, 
3H, CH3-C7); 2.40 (s, 3H, CH3-C3). Anal. Calcd. for C19H17N3O5: C, 62.12%; H, 
4.66%; N, 11.44%. Found: C, 61.74%; H, 4.80%; N, 11.68%. 
6.1.5.43. 6,7-dichloro-3-methylquinoxaline-2-carboxylic acid (benzo[1,3]dioxol-5-
ylmethyl) amide 1,4-di-N-oxide (9g). Yield: 22%. IR (KBr): 3273 (w, N-H); 3058 (w, 
arC-H); 1647 (s, C=O); 1326 (s, N+O-). 1H NMR (400 MHz, DMSO-d6) δ ppm: 9.31 (t, 
1H, NH, JNH-CH2= 5.8 Hz); 8.69 (s, 1H, H5); 8.67 (s, 1H, H8); 7.02 (bs, 1H, H2’); 6.90 
(bs, 2H, H5’+H6’); 6.02 (bs, 2H, O-CH2-O); 4.46 (d, 2H, CH2); 2.50 (s, 3H, CH3-C3). 
Anal. Calcd. for C18H13Cl2N3O5: C, 51.20%; H, 3.10%; N, 9.95%. Found: C, 51.22%; 
H, 3.07%; N, 9.62%. 
6.2. Pharmacology[31] 
6.2.1. Primary Screening (Dose Response): Determination of a 90% Inhibitory 
Concentration (IC90). 
The initial screening is conducted against M.Tbc. H37Rv (ATCC 27294) in 
BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA).[32] 
Compounds are tested in ten 2-fold dilutions, typically from 100 µg/mL to 0.19 µg/mL. 
The IC90 is defined as the concentration effecting a reduction in fluorescence of 90% 
relative to controls. This value is determined from the dose-response curve using a 
curve-fitting program. Any IC90 value of ≤10µg/mL is considered "Active" for 
antitubercular activity. 
6.2.2. Secondary Screening: Determination of Mammalian Cell Cytotoxicity (CC50).  
 The VERO cell cytotoxicity assay is carried out in parallel with the TB Dose 
Response assay. After 72 hours exposure, viability is assessed using Promega’s Cell 
Titer Glo Luminescent Cell Viability Assay, a homogeneous method for determining 
the number of viable cells in culture based on quantitation of the ATP present. 
Cytotoxicity is determined from the dose-response curve as the CC50 using a curve 
fitting program. Then the CC50 is divided by the IC90 for calculating a Selectivity Index 
(SI) value. SI values of ≥ 10 are considered for further testing. 
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Scheme 1. General scheme of synthesis. 
 
Reagents and conditions: ia) acetic acid, diethyl ether, rt.; ib) methanol, Zn/NH4Cl aq.; 
ii) 2-hydroxypyridine, reflux; iii) methanol, 0ºC, N2 atmosphere; iv) methanol, CaCl2, 
ethanolamine. 
  
Table 1. Anti-tubercular activity of compounds (Series 1-9). 
 
a IC90 against M.tb H37Rv. 
b Cytotoxicity in VERO Cells. 
c Selectivity Index. 
d Not Tested. 
e Rifampin. 
 
